Physician profile
Michael M Johnson
NPI 1336538974
$2,663.81
in general payments reported to CMS, 2019-2025
23 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $14.93 · 2023: $597 · 2024: $750 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $439.22 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $355.12 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $286.32 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $276.54 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $211.37 | 2021-2023 | Xarelto |
| Pfizer INC. | $173.73 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.54 | 2023-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $118.72 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $102.92 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $98.57 | 2024-2025 | |
| Abbott Laboratories | $66.61 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $62.64 | 2023-2025 | Gardasil 9, Capvaxive, Steglatro |
| Glaxosmithkline, LLC. | $56.90 | 2025 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.97 | 2024-2025 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $46.48 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43.64 | 2023-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $43.16 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $33.95 | 2024-2025 | Voquezna |
| Abbvie INC. | $17.49 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.51 | 2023 | |
| Currax Pharmaceuticals LLC | $14.09 | 2025 | Contrave |
| Genentech USA, INC. | $13.49 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.83 | 2023 | Livalo, Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.